Medbot

What Medbot does

Shanghai MicroPort MedBot (Group) Co., Ltd. (MedBot) is a Shanghai-headquartered, HKEX-listed (SEHK: 2252) developer and manufacturer of surgical robotics systems, controlled by MicroPort Scientific Corporation. Founded in 2015 as an internal incubation project of the MicroPort group, the company has built a multi-specialty robotic surgery portfolio spanning laparoscopic (Toumai multi-port and single-port), orthopedic (SkyWalker for TKA/THA), vascular intervention (R-One), bronchoscopy (Trans-bronchial Surgical Robot), percutaneous procedures (ANT automated needle targeting), prostate biopsy (ISR'obot Mona Lisa), and 3D fluorescence imaging (DFVision). Its Toumai platform is the world's only commercial robotic surgery system compatible with 5G, GEO/LEO satellite, broadband and dedicated fiber networks, enabling transcontinental telesurgery demonstrated across more than 10,000 km. As of early 2026, cumulative orders exceeded 230 units across nearly 50 countries, with 100+ commercial installations reached in December 2025 and more than 15,000 multi-specialty procedures supported.

The company's revenue model is a hybrid of one-time capital equipment sales for robotic systems, recurring service and support contracts tied to the installed base, and ongoing instrumentation and consumables revenue per procedure. Pricing is enterprise quote-based and not publicly disclosed, consistent with medical device capital sales. Go-to-market combines direct enterprise field sales targeting top-tier hospitals and academic medical centers, channel partnerships through regional training hubs (IRCAD Strasbourg, ORSI Europe, Rajavithi Thailand, TechnoWave Egypt), and clinical validation at major surgical conferences (SRS, CUDA, EAU). Customer segments are primarily tertiary and academic medical centers, orthopedic surgery centers, national health systems seeking modernization (e.g., Egypt MoH), and multi-specialty private hospital groups. The company was awarded regulatory clearances spanning NMPA, FDA, CE, ANVISA, MHLW, ARTG, Health Canada, India CDSCO, and inclusion in UK NICE NHS guidance, alongside multiple design and innovation awards (Red Dot, iF, A'Design, SAIL, NICE EVA). FY2024 revenue of CNY 333.701m was offset by a CNY 478.596m net loss, reflecting continued investment in global commercialization and R&D.

Name

Medbot

Legal name

Shanghai MicroPort MedBot (Group) Co., Ltd.

Website

https://medbotsurgical.com

Company type

Public

Founded year

2015

Operating status

Operating

Headcount range

501–1,000 employees

Short description

MedBot is a Shanghai-based, HKEX-listed developer of multi-specialty surgical robotic systems (laparoscopic, orthopedic, vascular, bronchoscopy, biopsy), serving hospitals globally with its Toumai remote-surgery-capable platform across nearly 50 countries.

Ownership category

akta.pro rank

Product category

Surgical Robotics

NAICS

Surgical and Medical Instrument Manufacturing (339112), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Surgical Robotics & Computer-Assisted Surgery Platforms (HLAHADAF)

akta.pro secondary industries

Surgical Navigation, Robotics & Patient-Matched Instrumentation (Ortho/Spine) (HLAHAEAL), Healthcare & Assistive Robotics (HDAAAIAC), Surgical Navigation, Tracking & Intraoperative Guidance (Ortho/Neuro/ENT) (HLAHADAG)

Keywords

• Surgical robotics systems
• Robotic-assisted laparoscopic surgery
• Orthopedic surgical robots
• Remote telesurgery platforms
• Vascular intervention robotics

Headquarters

HQ city

Shanghai

HQ country

China

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Surgical Robot Systems Sales: Sale of robotic surgical systems including Toumai laparoscopic robots, SkyWalker orthopedic robots, and R-One vascular intervention robots. Revenue recognized upon installation and validation at customer sites.
2. Service and Support: Ongoing service contracts, maintenance, training, and technical support for installed systems. Provides recurring revenue from installed base.
3. Instrumentation and Consumables: Sale of surgical instruments, accessories, and consumables used with robotic systems during procedures.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Core offering

MedBot develops, manufactures, and commercializes robotic-assisted surgical systems for laparoscopic, orthopedic, vascular, trans-bronchial, and percutaneous procedures, including the Toumai multi-port and single-port laparoscopic robots, SkyWalker orthopedic robot for joint replacement, R-One vascular intervention robot, DFVision 3D electronic and fluorescence endoscopes, and ANT automated needle targeting system. The company also offers a remote surgery platform compatible with 5G, GEO/LEO satellites, broadband, and dedicated fiber, enabling ultra-low-latency (20-30ms) transcontinental telesurgery, complemented by instruments, consumables, service contracts, and clinical training programs.

Product overview

MedBot (Shanghai MicroPort MedBot Group Co., Ltd.) provides comprehensive robotic intelligent surgical total solutions across five major disciplines: laparoscopic, orthopedic, panvascular, trans-natural orifice, and percutaneous surgical solutions. The core product portfolio includes the Toumai® Laparoscopic Surgical Robot (multi-port and single-port versions) for general surgery, urology, gynecology, and thoracic procedures; the SkyWalker® Orthopedic Surgical Robot for joint replacement; the R-One® Vascular Intervention Robot for cardiovascular procedures; and specialized systems including the Trans-bronchical Surgical Robot, DFVision® 3D Electronic Laparoscope, DFVision® 3D Fluorescence Endoscope, ANT Automated Needle Targeting Robot, and ISR'obot™ Mona Lisa Prostate Puncture System. The company also offers the Toumai® Remote Surgical System enabling telesurgery across 5G, GEO/LEO satellite, and broadband networks. These products work together as an integrated ecosystem allowing surgeons to perform complex procedures with enhanced precision, remote capability, and AI-assisted planning.

Differentiator

Problem solved

Functional benefit

Brands

• Toumai: Laparoscopic Surgical Robot - multi-port and single-port robotic surgical systems for various surgical specialties including urology, general surgery, thoracic surgery, gynecology
• SkyWalker
• R-One
• DFVision
• ISRobot Mona Lisa
• SkyWalker
• Navibot

Products and services

• Toumai Multi-port Laparoscopic Surgical Robot Multi-port robotic-assisted laparoscopic surgical system with 3D high-definition visualization, intuitive master-slave teleoperation, and flexible surgical instruments. Applied across urology, general surgery, thoracic, gynecology, and pediatrics. First remote-capable surgical robot authorized for full-spectrum commercial clinical use globally, supporting telesurgery across 5G, GEO/LEO satellites, broadband, and fiber networks.
• Toumai Single-port Laparoscopic Surgical Robot Single-port version of the Toumai surgical robot with dual C-arm architecture and high-flexibility snake-like instruments enabling precision in tight anatomical spaces and wide-range multi-quadrant operations.
• SkyWalker Orthopedic Surgical Robot Orthopedic surgical robot for Total Knee Arthroplasty (TKA) and Total Hip Arthroplasty (THA) with AI-assisted preoperative planning, personalized implant plans, precise intraoperative registration and navigation, and lightweight high-precision robotic arm. Limits angle deviation to within 0.5 degrees, halves surgery time, and reduces blood loss by over 30%.
• R-One Vascular Intervention Robot Vascular intervention robot for cardiovascular procedures providing precise remote operation and execution of specific actions. Direct distant control operation reduces medical staff X-ray exposure risk while improving procedural safety and accuracy.
• DFVision 3D Electronic Laparoscope 3D electronic laparoscope with chip-on-tip structure including two high-resolution imaging objective lenses. Provides full HD resolution dual images with significantly reduced weight versus traditional optical structures, enabling 3D imaging and rich color performance for accurate surgical field presentation.
• DFVision 3D Fluorescence Endoscope Fluorescence imaging component of the Toumai Multi-Port Laparoscopic Surgical Robot offering multimodal fluorescence with eight display modes using indocyanine green (ICG) contrast agent. Achieves 10^-6 level optical filtering performance and enables real-time visualization of tissue function, blood perfusion, and tumor margins during surgery.
• ISR'obot Mona Lisa Robotic Prostate Puncture System High-end medical device for robot-assisted transperineal prostate biopsy guided by transrectal ultrasound. Combines trolley workstation with foot switches, mechanical arm with ultrasound probe fixators, bed rail stabilizer, and floor stand stabilizer for minimally invasive, accurate, stable, and safe prostate biopsy.
• Trans-bronchial Surgical Robot Surgical robot for bronchoscopy procedures integrating electromagnetic navigation and visual feedback with autopilot navigation through the bronchial tree, enabling precise autonomous reach to targeted lesions with minimal intervention.
• ANT (Automated Needle Targeting Robotics Systems) Automated needle targeting robot that analyzes X-ray or CT images, generates 2D/3D models, automatically calculates puncture paths, and transforms them to motion parameters for the puncture robot through AI algorithms. Used for percutaneous lung biopsy and percutaneous nephrolithotomy.
• Toumai Remote Surgical System Remote surgery platform compatible with 5G, GEO/LEO satellites, broadband, and dedicated fiber networks. Enables ultra-low latency (20-30ms) remote surgery across continents with over 700 remote robotic surgeries performed and 100% procedural success rate. Used across urology, general surgery, thoracic surgery, and gynaecology.

Quantifiable outcome

• 400+ remote surgeries with 100% success rate
• +6 more outcomes

Named customers15 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature10 records

Partnerships

Nine partnerships are on record, tiered core and major.

• IRCAD (Institute of Research against Digestive Cancer)coreStrategic or Co-development Partner · 16 July 2025Joint inauguration of dedicated Toumai Robotics Training Center in Strasbourg, France. IRCAD is world-renowned training and research center for minimally invasive surgery. Partnership serves as platform for global training, academic collaboration, and clinical research. Symbolizes fusion of remote surgery's historic breakthroughs with future innovation.
• Robocath (CathBot Joint Venture)coreStrategic or Co-development Partner · 1 January 2025Joint venture between Shanghai MicroPort MedBot and Robocath to form CathBot for vascular intervention robotics. Strategic partnership for developing and commercializing vascular intervention robotic systems. Enables expansion into endovascular robotics market segment.
• ORSI (Europe)majorStrategic or Co-development PartnerEuropean training and academic partnership supporting adoption of Toumai surgical robot. Part of growing international training network.
• NDR Medical TechnologymajorStrategic or Co-development PartnerStrategic partnership established for technology development and market expansion in surgical robotics.
• Biobot Surgical Ltd (Singapore)majorStrategic or Co-development PartnerStrategic partnership established for technology development and market expansion in surgical robotics.
• Dr. G. Viswanathan HospitalmajorImplementation/ SI/ Consulting PartnerKey clinical partner for trans-continental tele-robotic surgeries. Successfully performed two trans-continental tele-robotic surgeries between Belgium and Tiruchi (9,730 km). Demonstrates feasibility of remote robotic surgical care across continents.
• Rajavithi Hospital (Thailand Ministry of Health)majorImplementation/ SI/ Consulting PartnerThailand's top teaching hospital designated as official national training center for Toumai by Thailand Ministry of Health. Key partner for national training model in Asia-Pacific.
• TechnoWavemajorChannel Partner/ Reseller/ DistributorEgypt partnership meeting with Ministry of Health to discuss surgical robot technology activation. Collaboration to localize robotic surgical technology, enhance surgical precision, and establish remote training centers.
• Global Robotic Institute at Advent HealthmajorStrategic or Co-development PartnerFDA-IDE-approved remote robotic surgery partner. Dr. Vipul Patel performed first transcontinental robotic surgery on patient in Angola from Florida (7,000 miles). Pioneer in remote surgery clinical validation.

Scale indicators15 records

Recent moves10 records

Expansion highlights7 records

Direct peers

• Intuitive Surgical: Global market leader in robotic-assisted surgery with the da Vinci system, the dominant laparoscopic surgical robot. Direct competitor to MedBot's Toumai across urology, gynecology, thoracic, and general surgery, with thousands of installed systems worldwide.
• Stryker: Operates the MAKO robotic-arm assisted surgery platform, the leading orthopedic surgical robot for knee and hip arthroplasty. Direct competitor to MedBot's SkyWalker in the orthopedic robotics segment where Stryker has an entrenched installed base.
• Medtronic: Developed the Hugo robotic-assisted surgery platform targeting laparoscopic procedures, a direct competitor to Toumai. Also competes in spine and cranial robotics, with significant hospital relationships from its broader surgical business.
• Smith+Nephew: Markets the CORI handheld robotic-assisted surgical system for knee arthroplasty, a direct competitor to SkyWalker in orthopedic robotics. Competes in the same hospitals and uses similar surgeon-targeted sales motions.
• Zimmer Biomet: Develops the ROSA robotic platform for knee, hip, and spine surgery, a direct competitor to SkyWalker. Established orthopedic player leveraging its large joint reconstruction installed base.
• Globus Medical: Markets the ExcelsiusGPS robotic navigation and Excelsius3D imaging platform for spine surgery, a peer to SkyWalker in the orthopedic and spine robotics segment.
• Siemens Healthineers (Corindus): Develops the Corindus CorPath GRX vascular intervention robot, a direct competitor to MedBot's R-One in robotic-assisted cardiovascular procedures with remote capability.
• Robocath: French developer of vascular intervention robotics and CathBot joint venture partner with MedBot. Direct peer in endovascular robotics and a co-development collaborator on the R-One product family.

Broad incumbents

• Johnson & Johnson (Auris Health / Ethicon): Develops the MONARCH robotic bronchoscopy platform and Ottava laparoscopic system. A broad incumbent surgical robot player overlapping with MedBot's Toumai and Trans-bronchial product lines, leveraging its scale across surgical specialties.

Emerging players

• Asensus Surgical: Develops the Senhance laparoscopic robotic surgery platform with unique haptic feedback and eye-tracking. An emerging direct peer in laparoscopic surgical robotics competing with Toumai for share in cost-sensitive markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/profile.php?id=100088839135531
• LinkedInlinkedin.com/company/microport-medbot

Compliance11 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries1 record

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medbot